Literature DB >> 10958949

Lack of activating c-SRC mutations at codon 531 in rectal cancer.

M Nilbert1, E Fernebro.   

Abstract

Cellular SRC (c-SRC), which is the human homolog of the Rous sarcoma viral oncogene, v-src, is highly activated in colorectal cancer. Recently, a subset of colon cancers have shown a nonsense mutation at codon 531, which truncates c-SRC directly C-terminal to the c-SRC kinase regulatory domain. This specific mutation has been demonstrated to be activating, transforming, and tumorigenic and to promote metastasis. We investigated 100 rectal cancers, half of which had tumor spread outside the rectum, for this mutation by using direct sequencing. None of these tumors displayed any genetic alteration at this locus, and we thus conclude that the codon 531 mutation is a rare cause of c-SRC activation in rectal cancer.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10958949     DOI: 10.1016/s0165-4608(00)00226-0

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  11 in total

1.  c-src activating mutation analysis in Chinese patients with colorectal cancer.

Authors:  Ye-Xiong Tan; Han-Tao Wang; Peng Zhang; Zhong-Hua Yan; Guan-Long Dai; Meng-Chao Wu; Hong-Yang Wang
Journal:  World J Gastroenterol       Date:  2005-04-21       Impact factor: 5.742

2.  Combined inhibition of c-Src and epidermal growth factor receptor abrogates growth and invasion of head and neck squamous cell carcinoma.

Authors:  Priya Koppikar; Seung-Ho Choi; Ann Marie Egloff; Quan Cai; Shinsuke Suzuki; Maria Freilino; Hiroshi Nozawa; Sufi M Thomas; William E Gooding; Jill M Siegfried; Jennifer R Grandis
Journal:  Clin Cancer Res       Date:  2008-07-01       Impact factor: 12.531

3.  Targeted inhibition of SRC kinase signaling attenuates pancreatic tumorigenesis.

Authors:  Nagathihalli S Nagaraj; J Joshua Smith; Frank Revetta; M Kay Washington; Nipun B Merchant
Journal:  Mol Cancer Ther       Date:  2010-08-03       Impact factor: 6.261

Review 4.  Targeting SRC in glioblastoma tumors and brain metastases: rationale and preclinical studies.

Authors:  Manmeet S Ahluwalia; John de Groot; Wei Michael Liu; Candece L Gladson
Journal:  Cancer Lett       Date:  2010-12-08       Impact factor: 8.679

Review 5.  Targeting epidermal growth factor receptor and SRC pathways in head and neck cancer.

Authors:  Ann Marie Egloff; Jennifer R Grandis
Journal:  Semin Oncol       Date:  2008-06       Impact factor: 4.929

Review 6.  The role of Src in solid tumors.

Authors:  Deric L Wheeler; Mari Iida; Emily F Dunn
Journal:  Oncologist       Date:  2009-07-06

7.  Invasive prostate carcinoma driven by c-Src and androgen receptor synergy.

Authors:  Houjian Cai; Ivan Babic; Xiao Wei; Jiaoti Huang; Owen N Witte
Journal:  Cancer Res       Date:  2010-12-06       Impact factor: 12.701

8.  Downregulation of c-SRC kinase CSK promotes castration resistant prostate cancer and pinpoints a novel disease subclass.

Authors:  Chih-Cheng Yang; Ladan Fazli; Salvatore Loguercio; Irina Zharkikh; Pedro Aza-Blanc; Martin E Gleave; Dieter A Wolf
Journal:  Oncotarget       Date:  2015-09-08

9.  Improving Response Rates to EGFR-Targeted Therapies for Head and Neck Squamous Cell Carcinoma: Candidate Predictive Biomarkers and Combination Treatment with Src Inhibitors.

Authors:  Ann Marie Egloff; Jennifer Rubin Grandis
Journal:  J Oncol       Date:  2009-07-14       Impact factor: 4.375

10.  Dual-faced SH3BGRL: oncogenic in mice, tumor suppressive in humans.

Authors:  H Wang; B Liu; A Q O Al-Aidaroos; H Shi; L Li; K Guo; J Li; B C P Tan; J M Loo; J P Tang; M Thura; Q Zeng
Journal:  Oncogene       Date:  2015-10-12       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.